These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 27025703

  • 21. Paradoxical oncogenesis: are all BRAF inhibitors equal?
    Menzies AM, Kefford RF, Long GV.
    Pigment Cell Melanoma Res; 2013 Sep; 26(5):611-5. PubMed ID: 23795808
    [Abstract] [Full Text] [Related]

  • 22. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
    Birner P, Berghoff AS, Dinhof C, Pirker C, Capper D, Schoppmann SF, Petzelbauer P, von Deimling A, Berger W, Preusser M.
    Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
    [Abstract] [Full Text] [Related]

  • 23. ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.
    Rebocho AP, Marais R.
    Oncogene; 2013 Jun 27; 32(26):3207-12. PubMed ID: 22926515
    [Abstract] [Full Text] [Related]

  • 24. Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation.
    Grasso M, Estrada MA, Ventocilla C, Samanta M, Maksimoska J, Villanueva J, Winkler JD, Marmorstein R.
    ACS Chem Biol; 2016 Oct 21; 11(10):2876-2888. PubMed ID: 27571413
    [Abstract] [Full Text] [Related]

  • 25. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF.
    Hu J, Yu H, Kornev AP, Zhao J, Filbert EL, Taylor SS, Shaw AS.
    Proc Natl Acad Sci U S A; 2011 Apr 12; 108(15):6067-72. PubMed ID: 21441104
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.
    Jain P, Fierst TM, Han HJ, Smith TE, Vakil A, Storm PB, Resnick AC, Waanders AJ.
    Oncogene; 2017 Nov 09; 36(45):6348-6358. PubMed ID: 28806393
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.
    Mooz J, Oberoi-Khanuja TK, Harms GS, Wang W, Jaiswal BS, Seshagiri S, Tikkanen R, Rajalingam K.
    Sci Signal; 2014 Aug 05; 7(337):ra73. PubMed ID: 25097033
    [Abstract] [Full Text] [Related]

  • 30. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.
    Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, Van Belle P, Elder DE, Wang Y, Nathanson KL, Herlyn M.
    Oncogene; 2009 Jan 08; 28(1):85-94. PubMed ID: 18794803
    [Abstract] [Full Text] [Related]

  • 31. Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.
    Hirschi B, Gallmeier E, Ziesch A, Marschall M, Kolligs FT.
    Mol Cancer; 2014 May 24; 13():122. PubMed ID: 24885690
    [Abstract] [Full Text] [Related]

  • 32. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.
    Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R.
    Cell; 2010 Jan 22; 140(2):209-21. PubMed ID: 20141835
    [Abstract] [Full Text] [Related]

  • 33. Design, synthesis, and in vitro evaluation of N-(3-(3-alkyl-1H-pyrazol-5-yl) phenyl)-aryl amide for selective RAF inhibition.
    Jung H, Kim J, Im D, Moon H, Hah JM.
    Bioorg Med Chem Lett; 2019 Feb 15; 29(4):534-538. PubMed ID: 30630714
    [Abstract] [Full Text] [Related]

  • 34. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A, Arita T, Tsuchiya S, Donelan J, Chouitar J, Carideo E, Galvin K, Okaniwa M, Ishikawa T, Yoshida S.
    Cancer Res; 2013 Dec 01; 73(23):7043-55. PubMed ID: 24121489
    [Abstract] [Full Text] [Related]

  • 35. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.
    Wang P, Laster K, Jia X, Dong Z, Liu K.
    Mol Cancer; 2023 Dec 18; 22(1):208. PubMed ID: 38111008
    [Abstract] [Full Text] [Related]

  • 36. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, Schostack K, Simcox ME, Kopetz S, Heimbrook D, Lestini B, Bollag G, Su F.
    Cancer Res; 2012 Feb 01; 72(3):779-89. PubMed ID: 22180495
    [Abstract] [Full Text] [Related]

  • 37. Targeting oncogenic BRAF in human cancer.
    Pratilas CA, Xing F, Solit DB.
    Curr Top Microbiol Immunol; 2012 Feb 01; 355():83-98. PubMed ID: 21818706
    [Abstract] [Full Text] [Related]

  • 38. Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib.
    Tkacik E, Li K, Gonzalez-Del Pino G, Ha BH, Vinals J, Park E, Beyett TS, Eck MJ.
    J Biol Chem; 2023 May 01; 299(5):104634. PubMed ID: 36963492
    [Abstract] [Full Text] [Related]

  • 39. Molecular modeling, dynamics simulations, and binding efficiency of berberine derivatives: A new group of RAF inhibitors for cancer treatment.
    Jabbarzadeh Kaboli P, Ismail P, Ling KH.
    PLoS One; 2018 May 01; 13(3):e0193941. PubMed ID: 29565994
    [Abstract] [Full Text] [Related]

  • 40. Discovery of highly selective CRAF inhibitors, 3-carboxamido-2H-indazole-6-arylamide: In silico FBLD design, synthesis and evaluation.
    Aman W, Lee J, Kim M, Yang S, Jung H, Hah JM.
    Bioorg Med Chem Lett; 2016 Feb 15; 26(4):1188-92. PubMed ID: 26810260
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.